arrow
A

Ana Beatriz Gago-Veiga

Autonomous University of Madrid
H指数:20
被引数:1,129

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term atogepant for treatment-resistant migraine in real-world clinical practice: 12-month results (gema project)

长期阿托 gepant 用于治疗抵抗性偏头痛的真实世界临床实践:12个月结果(gema项目)

2026-09-150
OAAI
ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice

ESTELA研究:抗降钙素基因相关肽单克隆抗体在真实世界临床实践中的长期有效性与安全性

2026-06-250
OAAI
Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study

评估抗CGRP单克隆抗体在偏头痛和自身免疫性疾病患者中的有效性与安全性:IMMUNO-CGRP研究

IF0
2026-04-010
OAAI
Development and validation of a patient-reported-experience measure to ascertain treatment satisfaction in migraine: the MISAT-Q questionnaire

开发和验证一种患者报告体验量表以确定偏头痛治疗满意度:MISAT-Q问卷

2025-12-150
PRE
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response

阿托格匹兰坦在抗CGRP单克隆抗体治疗失败的偏头痛患者中的应用:一项关于疗效、安全性、持续性和应答预测因子的多中心真实世界研究

2025-11-280
OAAI
SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway–targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials

SAFE-CGRP研究:多中心回顾性评估在排除具有相关合并症或状况的受试者后,靶向CGRP通路的单克隆抗体在偏头痛中的安全性。

2025-11-270
OAAI
Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group

颅内压紊乱的诊断和治疗:西班牙神经病学学会头痛研究组的共识声明

2025-01-012
OAAI
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
2024-05-2210
PRE
Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review
2023-01-0616
OA
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
2022-02-1552
OA